Guido Franceschini

Summary

Affiliation: University of Milan
Country: Italy

Publications

  1. ncbi Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice
    G Franceschini
    Center E Grossi Paoletti and Institute of Pharmacological Sciences, University of Milano, Italy
    Arterioscler Thromb Vasc Biol 19:1257-62. 1999
  2. ncbi Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease
    G Franceschini
    Department of Pharmacological Sciences, University of Milan, Milan, Italy
    Am J Cardiol 88:9N-13N. 2001
  3. ncbi Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients
    Guido Franceschini
    Center E Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Italy
    Atherosclerosis 195:385-91. 2007
  4. ncbi Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant
    Monica Gomaraschi
    Center Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Italy
    Circulation 116:2165-72. 2007
  5. ncbi Structure and function of the apoA-IV T347S and Q360H common variants
    Monica Gomaraschi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, Universita degli Studi di Milano, 20133 Milano, Italy
    Biochem Biophys Res Commun 393:126-30. 2010
  6. ncbi Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans
    Laura Calabresi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, Universita degli Studi di Milano, 20133 Milano, Italy
    Circulation 120:628-35. 2009
  7. ncbi Synthetic high-density lipoproteins exert cardioprotective effects in myocardial ischemia/reperfusion injury
    Giuseppe Rossoni
    Department of Pharmacological Sciences, University of Milano, Italy
    J Pharmacol Exp Ther 308:79-84. 2004
  8. ncbi Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk
    Laura Calabresi
    Center E Grossi Paoletti, Universita degli Studi di Milano, Milano, Italy
    J Lipid Res 52:1569-74. 2011
  9. ncbi Novel missense variants in LCAT and APOB genes in an Italian kindred with familial lecithin:cholesterol acyltransferase deficiency and hypobetalipoproteinemia
    Paola Conca
    Center E Grossi Paoletti, Department of Pharmacological Sciences, Universita degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy
    J Clin Lipidol 6:244-50. 2012
  10. ncbi Functional LCAT is not required for macrophage cholesterol efflux to human serum
    Laura Calabresi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Milano, Italy
    Atherosclerosis 204:141-6. 2009

Collaborators

Detail Information

Publications52

  1. ncbi Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice
    G Franceschini
    Center E Grossi Paoletti and Institute of Pharmacological Sciences, University of Milano, Italy
    Arterioscler Thromb Vasc Biol 19:1257-62. 1999
    ..The high efficiency of A-IM-containing HDL for cell cholesterol uptake would result in an improved reverse cholesterol transport in the A-IM carriers, possibly explaining the low susceptibility to atherosclerosis development...
  2. ncbi Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease
    G Franceschini
    Department of Pharmacological Sciences, University of Milan, Milan, Italy
    Am J Cardiol 88:9N-13N. 2001
    ..Similarly, the risk associated with a low HDL-C level is of particular significance in patients with established coronary artery disease or with type 2 diabetes, and it is a more pertinent factor to consider when managing dyslipidemia...
  3. ncbi Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients
    Guido Franceschini
    Center E Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Italy
    Atherosclerosis 195:385-91. 2007
    ..The distinct and complementary effects of fenofibrate and simvastatin on lipid parameters and HDL-related biomarkers suggest that a combination therapy with the two drugs in dyslipidemic patients with low HDL would be fully justified...
  4. ncbi Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant
    Monica Gomaraschi
    Center Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Italy
    Circulation 116:2165-72. 2007
    ..Whether the low HDL level of apoA-I(M) carriers is associated with impaired vascular function is presently unknown...
  5. ncbi Structure and function of the apoA-IV T347S and Q360H common variants
    Monica Gomaraschi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, Universita degli Studi di Milano, 20133 Milano, Italy
    Biochem Biophys Res Commun 393:126-30. 2010
    ..The two common aminoacid substitutions have no effect on the ability of apoA-IV to maintain endothelial homeostasis...
  6. ncbi Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans
    Laura Calabresi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, Universita degli Studi di Milano, 20133 Milano, Italy
    Circulation 120:628-35. 2009
    ..Theoretically, hypoalphalipoproteinemia cases with LCAT deficiency should be at increased cardiovascular risk because of high-density lipoprotein deficiency and defective reverse cholesterol transport...
  7. ncbi Synthetic high-density lipoproteins exert cardioprotective effects in myocardial ischemia/reperfusion injury
    Giuseppe Rossoni
    Department of Pharmacological Sciences, University of Milano, Italy
    J Pharmacol Exp Ther 308:79-84. 2004
    ....
  8. ncbi Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk
    Laura Calabresi
    Center E Grossi Paoletti, Universita degli Studi di Milano, Milano, Italy
    J Lipid Res 52:1569-74. 2011
    ..The present findings support the concept that LCAT is not required for an efficient reverse cholesterol transport and that a low plasma LCAT concentration and activity is not associated with increased atherosclerosis...
  9. ncbi Novel missense variants in LCAT and APOB genes in an Italian kindred with familial lecithin:cholesterol acyltransferase deficiency and hypobetalipoproteinemia
    Paola Conca
    Center E Grossi Paoletti, Department of Pharmacological Sciences, Universita degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy
    J Clin Lipidol 6:244-50. 2012
    ..Mutations of APOB gene cause familial hypobetalipoproteinemia, a codominant disorder characterized by low plasma levels of LDL cholesterol and apoB...
  10. ncbi Functional LCAT is not required for macrophage cholesterol efflux to human serum
    Laura Calabresi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Milano, Italy
    Atherosclerosis 204:141-6. 2009
    ..To evaluate the capacity of serum from carriers of LCAT gene mutations to promote cell cholesterol efflux through the ABCA1, ABCG1, and SR-BI pathways...
  11. ncbi A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred
    Laura Calabresi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Italy
    Atherosclerosis 205:506-11. 2009
    ..To analyze the cholesteryl ester transfer protein (CETP) gene and the plasma HDL phenotype in a Caucasian subject with extremely elevated plasma high density lipoprotein-cholesterol (HDL-C)...
  12. ncbi Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease
    Laura Calabresi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, Universita degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy
    Atherosclerosis 222:299-306. 2012
    ..This paper reviews the genetic and biochemical features of LCAT deficiency, highlighting the absence of enhanced preclinical atherosclerosis in carriers, despite the remarkably low HDL cholesterol...
  13. ncbi Inhibition of MMP-2 activation and release as a novel mechanism for HDL-induced cardioprotection
    Stefano Bellosta
    Department of Pharmacological Sciences, University of Milano, Italy
    FEBS Lett 580:5974-8. 2006
    ..These results indicate prevention of MMP-2 activation as a novel mechanism for HDL-mediated cardioprotection...
  14. ncbi High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli
    Monica Gomaraschi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, Via Balzaretti 9, 20133 Milano, Italy
    Biochim Biophys Acta 1736:136-43. 2005
    ..38, P<0.001). By inhibiting IL-6 production and lowering plasma IL-6 concentration, HDL may limit the pro-atherogenic effects of both acute and chronic inflammatory states, of which IL-6 is a key orchestrator...
  15. ncbi The plasma concentration of Lpa-I:A-II particles as a predictor of the inflammatory response in patients with ST-elevation myocardial infarction
    Monica Gomaraschi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Italy
    Atherosclerosis 202:304-11. 2009
    ....
  16. ncbi An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia
    Laura Calabresi
    Center E. Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Milan, Italy
    Metabolism 53:153-8. 2004
    ..The plasma concentration of the HDL-bound antioxidant enzyme paraoxonase increased by 10% after Omacor. Omacor may be helpful in correcting multiple lipoprotein abnormalities and reducing cardiovascular risk in FCHL patients...
  17. ncbi Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations
    Monica Gomaraschi
    Center Enrica Grossi Paoletti, Department of Pharmacological Sciences, Universita degli Studi di Milano, Milano, Italy
    Clin Chim Acta 412:1262-5. 2011
    ..Objective of the present paper was to evaluate the impact of the L75P apoA-I variant on HDL subpopulations and cholesterol esterification in carriers...
  18. ncbi Severe high-density lipoprotein deficiency associated with autoantibodies against lecithin:cholesterol acyltransferase in non-Hodgkin lymphoma
    Sara Simonelli
    Department of Pharmacological Sciences, Universita degli Studi di Milano, 20133 Milano, Italy
    Arch Intern Med 172:179-81. 2012
    ..To our knowledge, an acquired LCAT deficiency leading to severe HD has not been reported previously in association with a malignant disease, and this patient represents the first such documented case...
  19. ncbi A model structure for the heterodimer apoA-IMilano-apoA-II supports its peculiar susceptibility to proteolysis
    Alessandro Guerini Rocco
    Gruppo di Studio per la Proteomica e la Struttura delle Proteine, Centro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche, , Milan, Italy
    Biophys J 91:3043-9. 2006
    ..Circular dichroism on synthetic HDL containing apoA-I(M)-apoA-II was consistent with the alpha-helix content computed on the proposed model...
  20. ncbi High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease
    Monica Gomaraschi
    Center E. Grossi Paoletti, Department of Pharmacological Sciences, University of Milan, Italy
    Expert Opin Ther Targets 10:561-72. 2006
    ..Therapeutic interventions raising plasma HDL levels or directly mimicking its beneficial effects represent the next frontier in the prevention and treatment of cardiovascular disease...
  21. ncbi Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice
    G Chiesa
    Center E Grossi Paoletti and Institute of Pharmacological Sciences, University of Milano, Italy
    Arterioscler Thromb Vasc Biol 18:1417-23. 1998
    ....
  22. ncbi Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3
    Livia Pisciotta
    Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, Genoa, Italy
    Circ Cardiovasc Genet 5:42-50. 2012
    ..Recently, 4 related individuals with primary hypolipidemia were found to be compound heterozygotes for ANGPTL3 loss-of-function mutations...
  23. ncbi Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases
    Laura Calabresi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, 20133 Milano, Italy
    Curr Atheroscler Rep 8:163-7. 2006
    ..Although at early stages of drug development, A-I(M)/A-I(M) sHDL holds vast promise for the treatment of a variety of cardiovascular diseases in humans...
  24. ncbi Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol
    Laura Calabresi
    Center E. Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Italy
    Arterioscler Thromb Vasc Biol 22:656-61. 2002
    ..An increased CAMs expression may be a mechanism by which a low plasma HDL level promotes atherogenesis and causes acute atherothrombotic events...
  25. ncbi The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families
    Laura Calabresi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, 20133 Milan, Italy
    Arterioscler Thromb Vasc Biol 25:1972-8. 2005
    ..To better understand the role of lecithin:cholesterol acyltransferase (LCAT) in lipoprotein metabolism through the genetic and biochemical characterization of families carrying mutations in the LCAT gene...
  26. ncbi High-density lipoprotein quantity or quality for cardiovascular prevention?
    Laura Calabresi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, Universita degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy
    Curr Pharm Des 16:1494-503. 2010
    ....
  27. ncbi Size is a major determinant of dissociation and denaturation behaviour of reconstituted high-density lipoproteins
    Elisabetta Gianazza
    Gruppo di Studio per la Proteomica e la Struttura delle Proteine, Dipartimento di Scienze Farmacologiche, Universita degli Studi di Milano, via G Balzaretti 9, I 20133 Milano, Italy
    Biochem J 366:245-53. 2002
    ..5/12.7 nm rHDL is likely connected to the higher number of protein-lipid and lipid-lipid interactions in larger as compared with smaller rHDL...
  28. ncbi Denaturation and self-association of apolipoprotein A-I investigated by electrophoretic techniques
    E Gianazza
    Istituto di Scienze Farmacologiche and Centro Enrica Grossi Paoletti, Facolta di Farmacia, Universita di Milano, Italy
    Biochemistry 36:7898-905. 1997
    ..At acidic pH, apoA-I does not form aggregates and has little secondary structure; unfolding is then a progressive rather than a cooperative process...
  29. ncbi Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study
    C R Sirtori
    Center E Grossi Paoletti, Institute of Pharmacological Sciences, University of Milano, Milan, Italy
    Circulation 103:1949-54. 2001
    ..The objective of this study was to establish whether this high-risk lipid/lipoprotein profile is associated with structural changes in the carotid arteries and heart, indicative of preclinical atherosclerosis...
  30. ncbi Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks
    Giulia Chiesa
    Department of Pharmacological Sciences, University of Milano, Italy
    Circ Res 90:974-80. 2002
    ..These results suggest AIM-PL complexes enhanced lipid removal from arteries is the mechanism responsible for the observed plaque changes...
  31. ncbi Endothelial protection by high-density lipoproteins: from bench to bedside
    Laura Calabresi
    Center E. Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Italy
    Arterioscler Thromb Vasc Biol 23:1724-31. 2003
    ....
  32. ncbi High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release
    Laura Calabresi
    Center E. Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Italy
    Circ Res 92:330-7. 2003
    ..A low plasma HDL level may expose the heart to excessive ischemia-reperfusion damage, and HDL-targeted therapies may be helpful to induce immediate or delayed myocardial protection from ischemia-reperfusion injury...
  33. ncbi Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans
    Laura Calabresi
    Center E Grossi Paoletti, Department of Pharmacological Sciences, Universita degli Studi di Milano, 20133 Milano, Italy
    Trends Cardiovasc Med 20:50-3. 2010
    ..These findings challenge the notion that LCAT is required for effective atheroprotection and suggest that elevating LCAT expression and/or activity is not a promising therapeutic strategy to reduce cardiovascular risk...
  34. ncbi Limited proteolysis of a disulfide-linked apoA-I dimer in reconstituted HDL
    L Calabresi
    Center E. Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, 20133 Milano, Italy
    J Lipid Res 42:935-42. 2001
    ..This suggests the presence of a novel carboxy-terminal domain in A-I(M)/A-I(M), not organized in a compact structure and not shared by wild-type apoA-I, which may account for the unique functional properties of A-I(M)/A-I(M)...
  35. ncbi Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population
    J P Werba
    Center E Grossi Paoletti, University of Milan, Italy
    Atherosclerosis 101:203-11. 1993
    ..In HC patients, the presence of tendon xanthomas was associated with twofold higher Lp(a) levels. These findings argue for a regulatory role of triglycerides on plasma Lp(a) levels in hyperlipidemic patients...
  36. ncbi Apolipoprotein AIMilano. Partial lecithin:cholesterol acyltransferase deficiency due to low levels of a functional enzyme
    G Franceschini
    Center E Grossi Paoletti, Institute of Pharmacological Sciences, University of Milan, Italy
    Biochim Biophys Acta 1043:1-6. 1990
    ....
  37. ncbi Increased carotid artery intima-media thickness in subjects with primary hypoalphalipoproteinemia
    Damiano Baldassarre
    Center E. Grossi Paoletti, Department of Pharmacological Sciences, University of Milan, Italy
    Arterioscler Thromb Vasc Biol 22:317-22. 2002
    ....
  38. ncbi Synthetic HDL as a new treatment for atherosclerosis regression: has the time come?
    Paola Conca
    Center E Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Via Balzaretti 9, 20133 Milano, Italy
    Nutr Metab Cardiovasc Dis 18:329-35. 2008
    ..Although at early stages of drug development, sHDL hold vast promise for plaque stabilization/regression, and cardiovascular event reduction...
  39. ncbi Management of lipoprotein-X accumulation in severe cholestasis by semi-selective LDL-apheresis
    G Franceschini
    Center E Grossi Paoletti, University of Milano, Italy
    Am J Med 90:633-8. 1991
    ..The reduction of plasma cholesterol levels was associated with a complete regression of the xanthomas, supporting DF apheresis as a first-choice treatment for patients with massive LP-X accumulation due to cholestasis...
  40. ncbi Development of a lipid-rich, soft plaque in rabbits, monitored by histology and intravascular ultrasound
    G Chiesa
    Institute of Pharmacological Sciences, University of Milano, Via Balzaretti 9, 20133, Milano, Italy
    Atherosclerosis 156:277-87. 2001
    ..The easy accessibility of the arterial lesion allows serial IVUS investigations and the direct evaluation of a number of locally or generally delivered therapeutic agents...
  41. ncbi Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma
    T Murakami
    Center E Grossi Paoletti, Institute of Pharmacological Sciences, University of Milano, Italy
    Arterioscler Thromb Vasc Biol 15:1819-28. 1995
    ....
  42. ncbi Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux
    Miriam Lee
    Wihuri Research Institute, Helsinki, Finland
    J Lipid Res 44:539-46. 2003
    ..This observation supports the concept that limited extracellular proteolysis of apoA-I is one pathophysiologic mechanism leading to the generation and maintenance of foam cells in atherosclerotic lesions...
  43. ncbi Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux
    Miriam Lee
    Wihuri Research Institute, Helsinki, Finland
    Arterioscler Thromb Vasc Biol 22:1475-81. 2002
    ....
  44. ncbi Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein
    Elda Favari
    Department of Pharmacological and Biological Sciences, and Applied Chemistry, University of Parma, Italy
    J Biol Chem 279:9930-6. 2004
    ..Our results are compatible with the view that HDL(3) promotes ABCA1-mediated lipid efflux entirely through its lipid-poor fraction with pre-beta mobility...
  45. ncbi Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides
    Monica Gomaraschi
    National Institutes of Health, 10 Center Dr, Bldg 10 Rm 2C 433, Bethesda, MD 20892, USA
    J Pharmacol Exp Ther 324:776-83. 2008
    ....
  46. ncbi The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential
    Ilaria Zanotti
    Department of Pharmacological and Biological Sciences and Applied Chemistries, University of Parma, 43100 Parma, Italy
    J Lipid Res 49:954-60. 2008
    ....
  47. ncbi A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux
    Elda Favari
    Department of Pharmacological and Biological Sciences, and Applied Chemistries, University of Parma, Viale delle Scienze 27A, 43100 Parma, Italy
    J Biol Chem 282:5125-32. 2007
    ....
  48. ncbi Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism
    Sara Deakin
    Clinical Diabetes Unit, Division of Endocrinology and Diabetology, University Hospital, Geneva, 14, 1211 Switzerland
    J Biol Chem 277:4301-8. 2002
    ..The secretory process may be of importance for assuring the correct lipoprotein destination of PON1 and thus its functional efficiency...
  49. ncbi Role of LCAT in HDL remodeling: investigation of LCAT deficiency states
    Bela F Asztalos
    Lipid Metabolism Laboratory, Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA
    J Lipid Res 48:592-9. 2007
    ....
  50. ncbi Recurrent mutations of the apolipoprotein A-I gene in three kindreds with severe HDL deficiency
    Livia Pisciotta
    Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, I 16132 Genoa, Italy
    Atherosclerosis 167:335-45. 2003
    ..These levels, however, were lower in L141R carriers than in carriers of c.85 del C. Haplotype analysis performed using several polymorphisms suggested that both the c.85 del C and L141R are likely to be recurrent mutations...
  51. ncbi Structure, function and amyloidogenic propensity of apolipoprotein A-I
    Laura Obici
    Centro per lo Studio e la Cura delle Amiloidosi Sistemiche, Laboratorio di Biotecnologie, IRCCS Policlinico San Matteo, Pavia, Italy
    Amyloid 13:191-205. 2006
    ....
  52. ncbi The C-terminal domain of apolipoprotein A-I is involved in ABCA1-driven phospholipid and cholesterol efflux
    Elda Favari
    Department of Pharmacological and Biological Sciences, and Applied Chemistry, University of Parma, Parco Area delle Scienze 27/A, 43100 Parma, Italy
    Biochem Biophys Res Commun 299:801-5. 2002
    ..Independent of the interaction with the cell surface, it may be the decreased ability of the truncated apoA-I to recruit membrane phospholipids that impairs its capacity to promote cell cholesterol efflux...